Skip to content
Open access

Molecular epidemiology of respiratory syncytial virus infections in Arizona, USA during the 2023-24 and 2024-25 seasons.

Sep 2026 · medRxiv · 0 citations
Medicine

TL;DR

During the 2023-24 and 2024-25 RSV seasons, unpaired nasopharyngeal swab specimens from patients presenting to Arizona healthcare systems with symptoms of influenza-like illness were collected to perform phylogenetic and genomic analyses to classify RSV genomes and detect mutations in the antigenic sites of the F protein and conserved central domain of the G protein.

Abstract

Respiratory syncytial virus infection is a common cause of hospitalizations in infants and elderly patients. With the increased availability of vaccines and therapeutic antibodies, surveilling the sequence landscape of viral genomes is important to increase awareness of potentially neutralizing mutations. During the 2023-24 and 2024-25 RSV seasons, we collected unpaired nasopharyngeal swab specimens from patients presenting to Arizona healthcare systems with symptoms of influenza-like illness. Using either tiled am-plicon-based enrichment or a commercial oligo hybrid-enrichment panel and next generation sequencing, we obtained genome sequences for RSV and co-infecting viruses. We performed phylogenetic and genomic analyses to classify RSV genomes and detect mutations in the antigenic sites of the F protein and conserved central domain of the G protein. Phylogenetic analysis showed RSV-A strains belonged to the A.D. 1, A.D.2, A.D.3, and A.D. 5 subclades. RSV-B genomes belonged to the B.D.4.1, B.D.4.1.1, B.D.E.1, B.D.E.5, and B.D.E. 7 clades. We found 9 polymorphic sites located in the antigenic sites of the F protein in our RSV-A genomes and 18 polymorphic sites in our RSV-B genomes over the two-season surveillance period. We identified 7 polymorphic sites in our RSV-A genomes and 8 polymorphic sites in our RSV-B genomes that are in the conserved central domain of the G protein. We also discovered 3 (6.7%) and 27 (15.8%) incidences of viral coinfections in the 2023-24 and 2024-25 seasons, respectively. Viral genomic surveil-lance plays an important role in maintaining the efficacy of vaccine and therapeutic agents. Continued monitoring of circulating variants is an important component of public health.

Read PDF

Similar papers

Open access Sep 2026

Genomic Surveillance Uncovers a Shift in Respiratory Syncytial Virus Subtype Dominance and the Local Expansion of Subclade B.D.E.1.7

Findings show that in the Boston metropolitan area, RSV subtype dominance continues to flip between seasons, and investigation of the clades within both subtypes did not reveal evidence of any virus seeding from the preceding season.

Emily LaVerriere, Sasha Behar, Yan-Mei Liang et al. · 0 citations
Open access Aug 2026

Molecular epidemiology of respiratory viral infections in hospitalized children in Novosibirsk, Russia, 2021–2023

The epidemiology of the analyzed viruses was consistent with worldwide surveillance trends and largely stable between the two later epidemic seasons, and in viral-bacterial association analysis the authors identified two significantly attracted pairs, in which virus is known to facilitate bacterial adherence to respira...

Denis E. Maslov, I. D. Osipov, D. S. Zabelina et al. · 0 citations
Open access Sep 2026

Molecular epidemiology of paediatric respiratory adenovirus infections in Île-de-France: findings from whole-genome sequencing

Abstract Background: Human adenoviruses (HAdVs) are a frequent cause of respiratory tract infections in children; however, their epidemiological patterns and genomic diversity remain insufficiently characterized in Europe. As respiratory HAdVs can cause outbreaks of acute and severe disease and show periodic re-emergen...

Maud Salmona, Elise Diaz, L. Feghoul et al. · 0 citations
Open access Sep 2026

Respiratory Syncytial Virus infections in immunosuppressed adults <65 years old: a comparative analysis with Influenza and SARS-CoV2

ObjectivesRespiratory Syncytial Virus (RSV) vaccine policies have varied globally since their approval in 2023. In the UK, policy has adapted in line with National evidence generation such that from Autumn 2026 at-risk persons [≥]65 years old will become eligible for vaccination. Immunosuppressed persons <65 years will...

M. Danysz, E. Barnes, S. Lim et al. · 0 citations
Open access Aug 2026

Genomic surveillance of enterovirus D68 circulating in 2025 reveals the emergence of a novel A2/B3 recombinant lineage

The identification of a novel A2–B3 recombinant lineage provides evidence of ongoing viral evolution through recombination, a mechanism that may alter transmissibility, virulence, or immune responses, and underscores the importance of whole-genome surveillance for accurate viral characterization.

Amary Fall, C. Morris, Omar Elgazayerly et al. · 0 citations
Open access Sep 2026

Epidemiology of human RSV in Taiwan, 2018–2024

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and older adults worldwide. This retrospective study investigated the epidemiology and molecular characteristics of RSV in Taiwan from 2018 to 2024 using data from the National Community Virus Surveillance System, whic...

Su-Lin Yang, Ming-Tsan Liu, H. Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.